| Bioactivity | Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers[1]. |
| Invitro | Clivatuzumab 对胰腺导管腺癌 (PDAC) 表现出高特异性，对正常和良性非肿瘤性胰腺组织几乎没有反应性，尽管它对某些其他器官(如胃、结肠、肺)的腺癌表现出有限的反应性(约占所有样本的 10%)[1]。 |
| Name | Clivatuzumab |
| CAS | 1622075-09-5 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gold DV, et al. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer. 2013 Nov 20;12(1):143. |